PTPI has 36-month beta value of 2.00. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PTPI is 24.49M, and currently, short sellers hold a 1.43% ratio of that float. The average trading volume of PTPI on March 17, 2025 was 7.76M shares.
PTPI) stock’s latest price update
The stock of Petros Pharmaceuticals Inc (NASDAQ: PTPI) has decreased by -5.45 when compared to last closing price of 0.08.Despite this, the company has seen a loss of -15.38% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-25 that Proprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) (“Petros” or the “Company”), a company focused on expanding consumer access to medication through over-the-counter (“OTC”) drug development programs, announces top-line results of its expanded Application Comprehension (“App Comp”) study, which determines consumer comprehension of its unique messaging within its proprietary Technology. In the study, the Company’s technology facilitated consumer’s understanding of designated critical objectives (with a success threshold of 90% or 85% based on clinical significance of the objective).
PTPI’s Market Performance
Petros Pharmaceuticals Inc (PTPI) has seen a -15.38% fall in stock performance for the week, with a -67.76% decline in the past month and a -77.41% plunge in the past quarter. The volatility ratio for the week is 14.47%, and the volatility levels for the past 30 days are at 24.53% for PTPI. The simple moving average for the past 20 days is -23.91% for PTPI’s stock, with a -76.15% simple moving average for the past 200 days.
PTPI Trading at -65.14% from the 50-Day Moving Average
After a stumble in the market that brought PTPI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.22% of loss for the given period.
Volatility was left at 24.53%, however, over the last 30 days, the volatility rate increased by 14.47%, as shares sank -73.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -80.02% lower at present.
During the last 5 trading sessions, PTPI fell by -16.54%, which changed the moving average for the period of 200-days by -87.17% in comparison to the 20-day moving average, which settled at $0.1048. In addition, Petros Pharmaceuticals Inc saw -79.74% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PTPI
Current profitability levels for the company are sitting at:
- -3.38 for the present operating margin
- 0.73 for the gross margin
The net margin for Petros Pharmaceuticals Inc stands at -2.63. The total capital return value is set at -1.67.
Based on Petros Pharmaceuticals Inc (PTPI), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -0.8. The debt to equity ratio resting at 2.33. The interest coverage ratio of the stock is -26.17.
Currently, EBITDA for the company is -4.21 million with net debt to EBITDA at -3.37. When we switch over and look at the enterprise to sales, we see a ratio of 1.41. The receivables turnover for the company is 2.06for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.85.
Conclusion
To put it simply, Petros Pharmaceuticals Inc (PTPI) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
